Compare · CI vs DGX
CI vs DGX
Side-by-side comparison of The Cigna Group (CI) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $72.53B, about 3.4x DGX ($21.28B).
- DGX has been more active in the news (12 items in the past 4 weeks vs 7 for CI).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Quest Diagnostics Incorporated
- Price
- $274.25-1.11%
- $192.18-1.46%
- Market cap
- $72.53B
- $21.28B
- 1M return
- -
- -1.19%
- 1Y return
- -
- +10.22%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 12
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CI
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook
Latest DGX
- Director Carter Robert B was granted 1,142 shares, increasing direct ownership by 42% to 3,853 units (SEC Form 4)
- Director Gregg Vicky B was granted 1,142 shares, increasing direct ownership by 7% to 18,314 units (SEC Form 4)
- Director Main Timothy L was granted 1,142 shares, increasing direct ownership by 4% to 27,439 units (SEC Form 4)
- Director Diaz Luis was granted 1,142 shares, increasing direct ownership by 28% to 5,196 units (SEC Form 4)
- Director Wentworth Timothy C was granted 1,142 shares, increasing direct ownership by 529% to 1,358 units (SEC Form 4)
- Director Doi Tracey was granted 1,142 shares, increasing direct ownership by 17% to 7,748 units (SEC Form 4)
- Director Ring Timothy M was granted 1,142 shares, increasing direct ownership by 4% to 31,140 units (SEC Form 4)
- Director Lassiter Wright Iii was granted 1,142 shares, increasing direct ownership by 12% to 10,317 units (SEC Form 4)
- Director Morrison Denise M was granted 1,142 shares, increasing direct ownership by 11% to 11,929 units (SEC Form 4)
- Director Pfeiffer Gary M was granted 1,142 shares, increasing direct ownership by 4% to 31,005 units (SEC Form 4)